Disorders Associated with Acute Rapid and Severe Bone Loss

Journal of Bone and Mineral Research

Volumn 18, Issue 12, 2003, Pages 2083-2094

  Epstein, Solomon ^a,c   Inzerillo, Angela M ^a   Caminis, John ^b   Zaidi, Mone ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Mount Sinai University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCITONIN; CALCIUM; CYCLOSPORIN A; ESTROGEN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHONIC ACID DERIVATIVE; RAPAMYCIN; RECOMBINANT HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TACROLIMUS; VITAMIN D;

AGED; BONE DEVELOPMENT; BONE DISEASE; BONE MARROW TRANSPLANTATION; BONE MASS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ESTROGEN THERAPY; FRACTURE; HEART TRANSPLANTATION; HUMAN; IMMOBILIZATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MENOPAUSAL SYNDROME; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PANCREAS TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; REVIEW; RHEUMATOID ARTHRITIS; STROKE; SURGICAL INFECTION; SYSTEMIC DISEASE;

BONE DISEASES, METABOLIC; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION;

EID: 0344011534     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.12.2083     Document Type: Review

References (164)

1. Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME 2003 Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: A randomized controlled trial. Arch Intem Med 163:789-794.
2. Tremollieres FA, Pouilles JM, Ribot C 2001 Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteoporos Int 12: 385-390.
3. Cundy T, Cornish J, Roberts H, Reid IR 2002 Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol 186:978-983.
4. Cundy T, Farquhar CM, Cornish J, Reid IR 1996 Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women. J Clin Endocrinol Metab 81: 1014-1017.
5. Riggs BL, Khosla S, Melton LJ III 1998 A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773.
6. Rodino MA, Shane E 1998 Osteoporosis after organ transplantation. Am J Med 104:459-469.
7. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
8. Manolagas SC, Weinstein RS 1999 New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14:1061-1066.
9. Cooper MS, Hewison M, Stewart PM 1999 Glucocorticoid activity, inactivity and the osteoblast. J Endocrinol 163:159-164.
10. Dempster DW 1989 Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137-141.
11. Peel NF, Moore DJ, Barrington NA, Bax DE, Eastell R 1995 Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801-806.
12. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J 1991 Vertebral fractures in steroid dependent asthma and involutional osteoporosis: A comparative study. Thorax 46: 803-806.
13. Canalis E 1996 Clinical review 83. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 81:3441-3447.
14. Libanati CR, Baylink DJ 1992 Prevention and treatment of glucocorticoid-induced osteoporosis. A pathogenetic perspective. Chest 102:1426-1435.
15. Walsh LJ, Wong CA, Pringle M, Tattersfield AE 1996 Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: A cross sectional study. BMJ 313:344-346.
16. Reid IR 1998 Glucocorticoid induced osteoporosis: Assessment and treatment. J Clin Densitom 1:65-73.
17. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000.
18. Adinoff AD, Hollister JR 1983 Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265-268.
19. Cooper C, Coupland C, Mitchell M 1995 Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 54:49-52.
20. American College of Rheumatology Ad Hoc Committee on Glucocordcoid-Induced Osteoporosis 2001 Recommendations for the prevention and treatment of glucocorticoid-inducedosteoporosis: 2001 update. Arthritis Rheum 44:1496-1503.
21. Saag KG 2003 Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am 32:135-157.
22. Clowes JA, Peel N, Eastell R 2001 Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 13:326-332.
23. Sambrook PN 2000 Perspective corticosteroid osteoporosis: Practical implications of recent trials. J Bone Miner Res 15:1645-1649.
24. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS 2001 Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345:941-947.
25. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292-299.
26. van Staa TP, Cooper C, Leufkens HG, Bishop N 2003 Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 18:913-918.
27. Baltzan MA, Suissa S, Bauer DC, Cummings SR 1999 Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group. Lancet 353:1327.
28. Dempster DW 2000 The contribution of trabecular architecture to cancellous bone quality. J Bone Miner Res 15:20-23.
29. Canalis E, Giustina A 2001 Glucocorticoid-induced osteoporosis: Summary of a workshop. J Clin Endocrinol Metab 86:5681-5685.
30. Manolagas SC 2000 Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115-137.
31. Canalis E, Delany AM 2002 Mechanisms of glucocorticoid action in bone. Ann NY Acad Sci 966:73-81.
32. Clowes JA, Peel N, Eastell R 2001 Glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 13:326-332.
33. Nishimura J, Ikuyama S 2000 Glucocorticoid-induced osteoporosis: Pathogenesis and management. J Bone Miner Metab 18: 350-352.
34. Reid IR 2000 Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 14:279-298.
35. Jowell PS, Epstein S, Fallon MD, Reinhardt TA, Ismail F 1987 1,25-Dihydroxyvitamin D3 modulates glucocorticoid-induced alteration in serum bone Gla protein and bone histomorphometry. Endocrinology 120:531-536.
36. King CS, Weir EC, Gundberg CW, Fox J, Insogna KL 1996 Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 59:184-191.
37. Subramaniam M, Colvard D, Keeting PE, Rasmussen K, Riggs BL, Spelsberg TC 1992 Glucocorticoid regulation of alkaline phosphatase, osteocalcin, and proto-oncogenes innormal human osteoblast-like cells. J Cell Biochem 50:411-424.
38. Gronowicz GA, DeRome ME, McCarthy MB 1991 Glucocorticoids inhibit fibronectin synthesis and messenger ribonucleic acid levels in cultured fetal rat parietal bones. Endocrinology 128: 1107-1114.
39. Doherty WJ, DeRome ME, McCarthy MB, Gronowicz GA 1995 The effect of glucocorticoids on osteoblast function. The effect of corticosterone on osteoblast expression of beta 1 integrins. J Bone Joint Surg Am 77:396-404.
40. Gohel AR, Hand AR, Gronowicz GA 1995 Immunogold localization of beta 1-integrin in bone: Effect of glucocorticoids and insulin-like growth factor I on integrins and osteocyte formation. J Histochem Cytochem 43:1085-1096.
41. Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M 1998 Reduction in transforming growth factor beta receptor I expression and transcription factor CBFa1 on bone cells by glucocorticoid. J Biol Chem 273:4892-4896.
42. Okazaki R, Riggs BL, Conover CA 1994 Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells. Endocrinology 134:126-132.
43. Gabbitas B, Canalis E 1996 Cortisol enhances the transcription of insulin-like growth factor-binding protein-6 in cultured osteoblasts. Endocrinology 137:1687-1692.
44. Vidal NO, Brandstrom H, Jonsson KB, Ohlsson C 1998 Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol 159: 191-195.
45. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140: 4382-4389.
46. Doerr P, Pirke KM 1976 Cortisol-induced suppression of plasma testosterone in normal adult males. J Clin Endocrinol Metab 43:622-629.
47. Hsueh AJ, Erickson GF 1978 Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 32:639-648.
48. Caniggia A, Nuti R, Lore F, Vattimo A 1981 Pathophysiology of the adverse effects of glucoactive corticosteroids on calcium metabolism in man. J Steroid Biochem Mol Biol 15:153-161.
49. Reid IR, Ibbertson HK 1987 Evidence for decreased tubular reabsorption of calcium in glucocorticoid-treated asthmatics. Horm Res 27:200-204.
50. Rubin M, Bilezikian J 2002 The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A reexamination of the evidence. J Clin Endocrinol Metab 87:4033-4041.
51. 1999 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network: Transplant Data 1989-1998. HHS/HRSA/OSP/DOT and UNOS: Rockville, MD, USA and Richmond, VA, USA.
52. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P 1996 Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 26:549-555.
53. Rich GM, Mudge GH, Laffel GL, LeBoff MS 1992 Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant 11:950-958.
54. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S 1988 Cyclosporin-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration. Endocrinology 123:2571-2577.
55. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S 1989 Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption. J Bone Miner Res 4:393-398.
56. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S 1989 The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 124:2179-2184.
57. Epstein S, Takizawa M, Stein B, Katz IA, Joffe II, Romero DF, Liang XG, Li M, Ke HZ, Jee WS 1994 Effect of cyclosporin A on bone mineral metabolism in experimental diabetes mellitus in the rat. J Bone Miner Res 9:557-566.
58. Stein B, Halloran BP, Reinhardt T, Engstrom GW, Bales CW, Drezner MK, Currie KL, Takizawa M, Adams JS, Epstein S 1991 Cyclosporin-A increases synthesis of 1,25-dihydroxyvitamin D3 in the rat and mouse. Endocrinology 128:1369-1373.
59. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, Epstein S 1994 The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57:1231-1237.
60. Stempfle HU 1996 Osteoporosis following heart transplantation. Pathogenesis and therapy. Dtsch Med Wochenschr 121:1103-1107.
61. Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG, Ma YF, Jee WS, Epstein S 1995 Rapamycin: A bone sparing immunosuppressant? J Bone Miner Res 10:760-768.
62. Dissanayake IR, Goodman GR, Bowman AR, Ma Y, Pun S, Jee WS, Epstein S 1998 Mycophenolate mofetil: A promising new immunosuppressant that does not cause bone loss in the rat. Transplantation 65:275-278.
63. Goodman GR, Dissanayake IR, Sodam BR, Gorodetsky E, Lu J, Ma YF, Jee WS, Epstein S 2001 Immunosuppressant use without bone loss-implications for bone loss after transplantation. J Bone Miner Res 16:72-78.
64. Bryer HP, Isserow JA, Armstrong EC, Mann GN, Rucinski B, Buchinsky FJ, Romero DF, Epstein S 1995 Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 10:132-138.
65. Buchinsky FJ, Ma Y, Mann GN, Rucinski B, Bryer HP, Romero DF, Jee WS, Epstein S 1996 T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 137:2278-2285.
66. Shui C, Riggs BL, Khosla S 2002 The immunosuppressant rapamycin, alone or with transforming growth factor-beta, enhances osteoclast differentiation of RAW264.7 monocyte-macrophage cells in the presence of RANK-ligand. Calcif Tissue Int 71:437-446.
67. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, Epstein S 1994 The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57:1231-1237.
68. Rucinski B, Liu CC, Epstein S 1994 Utilization of cyclosporine H to elucidate the possible mechanisms of cyclosporine A-induced osteopenia in the rat. Metabolism 43:1114-1118.
69. Walsh CT, Zydowsky LD, McKeon FD 1992 Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 267:13115-13118.
70. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW 1984 Cyclophilin: A specific cytosolic binding protein for cyclosporin A. Science 226:544-547.
71. Siekierka JJ, Sigal NH 1992 FK-506 and cyclosporin A: Immunosuppressive mechanism of action and beyond. Curr Opin Immunol 4:548-552.
72. Awumey EM, Moonga BS, Sodam BR, Koval AP, Adebanjo OA, Kumegawa M, Zaidi M, Epstein S 1999 Molecular and functional evidence for calcineurin-A alpha and beta isoforms in the osteoclast: Novel insights into cyclosporin A action on bone resorption. Biochem Biophys Res Commun 254:248-252.
73. Sun L, Adebanjo OA, Liu XH, Moonga BS, Inzerillo A, Koval A, Wu XY, Wu XB, Bevis PJR, Blair HC, Conner D, Seidman J, Troen BR, Epstein S, Abe E, Zaidi M 2001 Dysfunctional osteoblasts, impaired osteoblastogenesis, reduced bone formation and severe osteoporosis in a Calcineurin Aα null mouse, molecular implications for understanding immunosuppressant bone loss. 23rd Annual Meeting of the ASBMR. Phoenix, AZ, USA, September 20-24, 2001, p. 1004.
74. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD 1991 Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544-550.
75. Casez JP, Lippuner K, Horber FF, Montandon A, Jaeger P 1992 Changes in bone mineral density over 18 months following kidney transplantation: The respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant 17:1318-1326.
76. Horber FF, Casez JP, Steiger U, Czerniak A, Montandon A, Jaeger P 1994 Changes in bone mass early after kidney transplantation. J Bone Miner Res 9:1-9.
77. Almond MK, Kwan JT, Evans K, Cunningham J 1994 Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron 66:52-57.
78. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, Langman CB, Salinger MH, Sprague SM 1999 Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res 14:456-463.
79. Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA 1998 Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 13:1250-1255.
80. Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B 1994 Fracture frequency after kidney transplantation. Transplant Proc 26:1764.
81. Chiu MY, Sprague SM, Bruce DS, Woodle ES, Thistlethwaite JR Jr, Josephson MA 1998 Analysis of fracture prevalence in kidney-pancreas allograft recipients. J Am Soc Nephrol 9:677-683.
82. Parry RG, Jackson J, Stevens JM, Higgins B, Altmann P 1998 Long-term bone densitometry post-renal transplantation in patients treated with either cyclosporin or prednisolone. Nephrol Dial Transplant 13:531-532.
83. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, Mancini DM, DiSesa VJ, Attie MF 1994 Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med 96: 35-41.
84. Anijar JR, Szejnfeld VL, Almeida DR, Fernandes AR, Ferraz MB 1999 Reduced bone mineral density in men after heart transplantation. Braz J Med Biol Res 32:413-420.
85. Glendenning P, Kent GN, Adler BD, Matz L, Watson I, O'Driscoll GJ, Hurley DM 1999 High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol (Oxf) 50:347-355.
86. Hetzer R, Albert W, Hummel M, Pasic M, Loebe M, Warnecke H, Haverich A, Borst HG 1997 Status of patients presently living 9 to 13 years after orthotopic heart transplantation. Ann Thorac Surg 64:1661-1668.
87. Pavie A, Dorent R, Reagan M, Akthar R, Leger P, Vaissier E, Levasseur JP, Bors V, Gandjbakhch I 1998 La Pitie heart transplantation: 30-year single center clinical experience. Clin Transpl 311-314.
88. Stempfle HU, Werner C, Echtler S, Wehr U, Rambeck WA, Siebert U, Uberfuhr P, Angermann CE, Theisen K, Gartner R 1999 Prevention of osteoporosis after cardiac transplantation: A prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68:523-530.
89. Garlicki AM, Orchowski F, Myrdko T, Wojcik S, Czerwinski E, Kukielka R, Kapelak B, Dziatkowiak A 1996 Measurement of radial bone mineral density in patients after heart transplantation. Ann Transplant 1:32-34.
90. Guo CY, Johnson A, Locke TJ, Eastell R 1998 Mechanisms of bone loss after cardiac transplantation. Bone 22:267-271.
91. Meys E, Terreaux-Duvert F, Beaume-Six T, Dureau G, Meunier PJ 1993 Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate. Osteoporos Int 3:322-329.
92. Muchmore JS, Cooper DK, Ye Y, Schlegel VT, Zuhdi N 1991 Loss of vertebral bone density in heart transplant patients. Transplant Proc 23:1184-1185.
93. Rich GM, Mudge GH, Laffel GL, LeBoff MS 1992 Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant 11:950-958.
94. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP 1993 Osteoporosis after cardiac transplantation. Am J Med 94:257-264.
95. Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, Mancini D, Michler RE, Aaronson K, Addesso V, Lo SH 1997 Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab 82:1497-1506.
96. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, Mancini D, Addesso V, Michler RE, Factor-Litvak P 1996 Fracture after cardiac transplantation: A prospective longitudinal study. J Clin Endocrinol Metab 81:1740-1746.
97. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, Otto G, Lange R, Theilmann L, Zimmerman R, Pritsch M, Ziegler R 2001 Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: A follow-up study. Lancet 357:342-347,
98. Idilman R, de Maria N, Uzunalimoglu O, van Thiel DH 1997 Hepatic osteodystrophy: A review. Hepatogastroenterology 44: 574-581.
99. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, Rimola A, Rodes J, Munoz-Gomez J 1997 Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation. Calcif Tissue Int 60:148-154.
100. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE 1999 Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int 64:295-300.
101. Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, Cedel SL, Riggs BL, Krom RA 1991 Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 14:296-300.
102. Isaia G, Di Stefano M, Roggia C, Ardissone P, Rosina F 1998 Bone disorders in cholestatic liver diseases. Forum (Genova) 8:28-38.
103. Abdelhadi M, Eriksson SA, Ljusk Eriksson S, Ericzon BG, Nordenstrom J 1995 Bone mineral status in end-stage liver disease and the effect of liver transplantation. Scand J Gastroenterol 30:1210-1215.
104. Watson RG, Coulton L, Kanis JA, Lombard M, Williams R, Neuberger J, Elias E 1990 Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with cyclosporin. J Hepatol 11:354-358.
105. Feller RB, McDonald JA, Sherbon KJ, McCaughan GW 1999 Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl 5:407-413.
106. Giannini S, Nobile M, Ciuffreda M, Iemmolo RM, Dalle Carbonare L, Minicuci N, Casagrande F, Destro C, Gerunda GE, Sartori L, Crepaldi G 2000 Long-term persistence of low bone density in orthotopic liver transplantation. Osteoporos Int 11: 417-424.
107. Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, Jorgesen B, McGregor C, Schulman L 1996 Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 101:262-269.
108. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D 1996 Severe osteoporosis before and afterlung transplantation. Chest 109:1176-1183.
109. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, Schulman LL 1999 Bone loss and fracture after lung transplantation. Transplantation 68:220-227.
110. Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, Bonjour JP, RizzoliR 1996 Osteoporosis in patients undergoing lung transplantation. Eur Respir J 9:2378-2382.
111. Haworth CS, Webb AK, Egan JJ, Selby PL, Hasleton PS, Bishop PW, Freemont TJ 2000 Bone histomorphometry in adult patients with cystic fibrosis. Chest 118:434-439.
112. Fine RN, Ho M, Tejani A 2001 The contribution of renal transplantation to final adult height: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Nephrol 16:951-956.
113. Kelly PJ, Atkinson K, Ward RL, Sambrook PN, Biggs JC, Eisman JA 1990 Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation 50: 881-883.
114. Castaneda S, Carmona L, Carvajal I, Arranz R, Diaz A, Garcia-Vadillo A 1997 Reduction of bone mass in women after bone marrow transplantation. Calcif Tissue Int 60:343-347.
115. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP 1999 Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342-350.
116. Castelo-Branco C, Rovira M, Pons F, Duran M, Sierra J, Vives A, Balasch J, Fortuny A, Vanrell J 1996 The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23:307-312.
117. Bikle DD, Halloran BP, Morey-Holton E 1997 Space flight and the skeleton: Lessons for theearthbound. Endocrinologist 7:10-22.
118. Rubin C, Gross T, Qin YX, Fritton S, Guilak F, McLeod K 1996 Differentiation of the bone-tissue remodeling response to axial and torsional loading in the turkey ulna. J Bone Joint Surg Am 78:1523-1533.
119. Srinivasan S, Gross TS 2000 Canalicular fluid flow induced by bending of a long bone. Med Eng Phys 22:127-133.
120. Ingber DE 1997 Tensegrity: The architectural basis of cellular mechanotransduction. Annu Rev Physiol 59:575-599.
121. Li XJ, Jee WS, Chow SY, Woodbury DM 1990 Adaptation of cancellous bone to aging and immobilization in the rat: A single photon absorptiometry and histomorphometry study. Anat Rec 227:12-24.
122. Lazo MG, Shirazi P, Sam M, Giobbie-Hurder A, Blacconiere MJ, Muppidi M 2001 Osteoporosis and risk of fracture in men with spinal cord injury. Spinal Cord 39:208-214.
123. Vestergaard P, Krogh K, Rejnmark L, Mosekilde L 1998 Fracture rates and risk factors for fractures in patients with spinal cord injury. Spinal Cord 36:790-796.
124. Dauty M, Perrouin Verbe B, Maugars Y, Dubois C, Mathe JF 2000 Supralesional and sublesional bone mineral density in spinal cord-injured patients. Bone 27:305-309.
125. Melton LJ III, Brown RD Jr, Achenbach SJ, O'Fallon WM, Whisnant JP 2001 Long-term fracture risk following ischemic stroke: A population-based study. Osteoporos Int 12:980-986.
126. Jorgensen L, Jacobsen BK 2001 Changes in muscle mass, fat mass, and bone mineral contentin the legs after stroke: A 1 year prospective study. Bone 28:655-659.
127. Ramnemark A, Nyberg L, Borssen B, Olsson T, Gustafson Y 1998 Fractures after stroke. Osteoporos Int 8:92-95.
128. Sato Y, Asoh T, Kondo I, Satoh K 2001 Vitamin D deficiency and risk of hip fractures among disabled elderly stroke patients. Stroke 32:1673-1677.
129. Kanis J, Oden A, Johnell O 2001 Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke 32:702-706.
130. Shane E, Epstein S 2001 Transplantation osteoporosis. Transplant Rev (Orlando) 15:11-32.
131. Heaney RP 1993 Nutritional factors in osteoporosis. Annu Rev Nutr 13:287-316.
132. Dawson-Hughes B 1991 Calcium supplementation and bone loss: A review of controlled clinical trials. Am J Clin Nutr 54:274S-280S.
133. NIH Consensus Development Panel on Optimal Calcium Intake 1994 NIH Consensus Conference: Optimal calcium intake. JAMA 272:1942-1948.
134. Sambrook P 1999 Alfacalcidol and calcitriol in the prevention of bone loss after organtransplantation. Calcif Tissue Int 65:341-343.
135. Henderson K, Eisman J, Keogh A, MacDonald P, Glanville A, Spratt P, Sambrook P 2001 Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res 16:565-571.
136. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, Bergin P, Ebeling P, Eisman J 2000 Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15:1818-1824.
137. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J 1993 Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 328:1747-1752.
138. Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC 2003 Prevention and treatment of glucocorticoid-induced osteoporosis: A comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919-924.
139. Lukert BP, Raisz LG 1990 Glucocorticoid-induced osteoporosis: Pathogenesis andmanagement. zjrnAnn Intern Med 112:352-364.
140. Hall GM, Daniels M, Huskisson EC, Spector TD 1994 A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 53:112-116.
141. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, Women's Health Initiative Investigators 2003 Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854.
142. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288:321-333.
143. Fletcher SW, Colditz GA 2002 Failure of estrogen plus progestin therapy for prevention. JAMA 288:366-368.
144. Reid IR, Wattie DJ, Evans MC, Stapleton JP 1996 Testosterone therapy in glucocorticoid-treated men. Arch Intem Med 156: 1173-1177.
145. Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD 1992 Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74:623-628.
146. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N 2000 Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 85:4500-4510.
147. Valero MA, Loinaz C, Larrodera L, Leon M, Moreno E, Hawkins F 1995 Calcitonin and bisphosphonates treatment in bone loss after liver transplantation. Calcif Tissue Int 57:15-19.
148. Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas JJ, Hawkins F 1997 Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiactransplantation. Calcif Tissue Int 60: 155-159.
149. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G 2000 Calcitonin for the treatment and prevention of corficosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983.
150. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ 1998 Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66:1004-1008.
151. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenen-house A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337: 382-387.
152. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA 2000 Effects of risedronate treatment on bone densityand vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285.
153. Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG 2000 Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients Osteoporos Int 11:331-337.
154. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA 1999 Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309-2318.
155. Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006-1013.
156. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: A randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202-211.
157. Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP 2001 Prevention of bone loss and fracture after lung transplantation: A pilot study. Transplantation 72:251-255.
158. Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, Burckhardt P 2001 Intravenous pamidronate as treatment for osteoporosis after heart transplantation: A prospective study. Osteoporos Int 12:112-116.
159. Nam JH, Moon JI, Chung SS, Kim SI, Park KI, Song YD, Kim KR, Lee HC, Huh K, Lim SK 2000 Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc 32:1876.
160. Aris RM, Lester GE, Renner JB, Winders A, Denene Blackwood A, Lark RK, Ontjes DA 2000 Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 162:941-946.
161. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R 2000 Bone mineral density in lung-transplant recipients before and after graft: Prevention of lumbar spine posttransplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 19:736-743.
162. Fan SL, Almond MK, Ball E, Evans K, Cunningham J 2000 Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684-690.
163. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP 1998 Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl 4:404-409.
164. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:1627-1633.